YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
3 Reasons to Avoid UTHR and 1 Stock to Buy Instead Since April 2026, United Therapeutics has been in a holding pattern, posting a small loss of 4.2% while floating around $541.72. The stock also fell short of the S&P 500's 17.5% gain durin…
Liquidia (LQDA) moved into the spotlight after a new court ruling in its patent fight with United Therapeutics over YUTREPIA, raising fresh questions about future labeling and market access. Recent trading reflects that uncertainty. Liquid…
[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Liquidia (LQDA [https://seekingalpha.com/symbol/LQDA]) is heading for its worst weekly decline on Friday after a legal setback in its patent dispute with United Therap…
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR)…
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:H…
Check out some of the companies making the biggest moves midday: Accenture — The global professional services company soared 18% following fiscal fourth-quarter results. Revenue of $18.7 billion exceeded the company's guidance of $17.8 bil…
Liquidia Corporation LQDA suffered a major setback after the U.S. District Court for the District of Delaware ruled that two claims of United Therapeutics' UTHR '327 patent are valid and infringed by Liquidia's lead drug Yutrepia. The ruli…
United Therapeutics UTHR announced that it has received a favorable ruling in its patent litigation against Liquidia Technologies LQDA concerning the latter's lead product, Yutrepia, a dry-powder inhaled formulation of treprostinil. UTHR s…
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled b…
TORONTO, Oct. 1, 2026 /CNW/ -- HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. Th…
United Therapeutics (UTHR) shares ended the last trading session 12.5% higher at $541.89. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.1% lo…
1 Mid-Cap Stock to Research Further and 2 That Underwhelm Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense c…
The Morning Bull - US Market Morning Update Thursday, Oct, 1 2026 US stock futures are pointing slightly higher this morning, with the S&P 500 mini contract up about 0.2% and the Nasdaq-100 mini edging 0.1% stronger, as investors weigh fre…
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled that competitor Liqu…
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 30, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of…
A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged. Continue Reading
Healthcare stocks declined late Wednesday afternoon with the NYSE Healthcare Index and the State Str PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Investing.com -- Liquidia Corp shares fell Wednesday after a U.S. District Court in Delaware ruled the company infringed two patent claims held by United Therapeutics Corp. United Therapeutics shares rose more than 13%. Before you buy NVID…
Liquidia Technologies, Inc. District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court's considerati…
Check out the companies making the biggest moves midday: Rogers — The maker of circuit materials surged 10% on better-than-expected earnings guidance. The company sees full-year earnings around $3.80 per share, excluding certain items, abo…
Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics Corporation (NASDAQ:UTHR) on September 24, 2026, with a Sell rating and a $321 price target. The firm argues that shares trade above their historical valuation…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
Earlier this week, Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, even as the company pursues an ambitious pipeline of 14 potential launches, including nebulized Tyvaso for idiopathic pulmonary fibrosis and onc…
United Therapeutics (UTHR) moved into focus after Goldman Sachs started coverage with a Sell rating, sending the stock down 4%, a meaningful single session move for a relatively steady biotech stock. Goldman's call lands after a choppy str…
Why United Therapeutics (UTHR) Shares Are Falling Today What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of the stock with a Sell ratin…
Liquidia Corporation LQDA is gaining strong commercial momentum with Yutrepia, but intensifying competition in the pulmonary arterial hypertension (PAH) market could make it increasingly challenging for the drug to sustain its growth traje…
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention…
1 Cash-Heavy Stock to Target This Week and 2 We Question A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsis…
Shares of Liquidia Corporation LQDA have lost 13.9% in a month against the industry's growth of 1.5%. The stock has lagged the broader sector and the S&P 500 Index. The selloff accelerated after Liquidia reported second-quarter results on…
It has been about a month since the last earnings report for Altimmune, Inc. (ALT). Shares have added about 14.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings releas…
United Therapeutics Corporation (NASDAQ:UTHR) committed the remaining $477.6 million under its $2 billion authorization to an accelerated share repurchase with Citibank, N.A. on September 8. Earlier transactions included $1.5 billion of ac…
Liquidia Corporation LQDA recently announced that the FDA has granted Fast Track designation to Yutrepia (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). Lead drug Yutr…
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Over t…
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN) Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next fe…
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 08, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previo…
Company Logo Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertensi…